1 | time | 94,828 |
2 | mini-monovision | 4 |
3 | 0.01° | 3 |
4 | 5yr | 3 |
5 | non-driving | 3 |
6 | philopatry | 3 |
7 | -26.52 | 2 |
8 | 40months | 2 |
9 | 55-years | 2 |
10 | 70-year-olds | 2 |
11 | al-buqratiya | 2 |
12 | apy+sal | 2 |
13 | ballistocardiograms | 2 |
14 | codon59 | 2 |
15 | complictions | 2 |
16 | dgu® | 2 |
17 | dose/time | 2 |
18 | ldhb | 2 |
19 | mans | 2 |
20 | microfeatures | 2 |
21 | multcomp | 2 |
22 | pd4-9 | 2 |
23 | pre-patent | 2 |
24 | tens-of-micrometers | 2 |
25 | trochar | 2 |
26 | 'discovery | 1 |
27 | +1.0°c | 1 |
28 | -pmr | 1 |
29 | 1,2-dibromoethane | 1 |
30 | 1,2-manner | 1 |
31 | 1.6-17.0 | 1 |
32 | 10.7±2.2 | 1 |
33 | 15-30s | 1 |
34 | 16-years-old | 1 |
35 | 20-30-minute | 1 |
36 | 200d | 1 |
37 | 21,641 | 1 |
38 | 30-mins | 1 |
39 | 382-fold | 1 |
40 | 42-atom-antidot | 1 |
41 | 42-km | 1 |
42 | 44oc | 1 |
43 | 5,000mg/kg/day | 1 |
44 | 5.00-6000ng/ml | 1 |
45 | 500kwhm | 1 |
46 | 501/mm3 | 1 |
47 | 6000mgl | 1 |
48 | 95+/-11 | 1 |
49 | apy+at | 1 |
50 | atg1δ | 1 |
51 | ballasts | 1 |
52 | bewertungsmabetastab | 1 |
53 | break-in | 1 |
54 | c2-carbon | 1 |
55 | case/images | 1 |
56 | cat-mv3glc- | 1 |
57 | cis-form | 1 |
58 | cohorte | 1 |
59 | complications/time | 1 |
60 | cuprophan | 1 |
61 | d-phe-cys-tyr-d-trp-orn-thr-pen | 1 |
62 | days-to-months | 1 |
63 | direct-detection | 1 |
64 | door-in | 1 |
65 | efficacy-stopping | 1 |
66 | endpoints/time | 1 |
67 | envi-carb/nh | 1 |
68 | epikeratome | 1 |
69 | evlt™ | 1 |
70 | exacerbations-free | 1 |
71 | exposion | 1 |
72 | filtre | 1 |
73 | force-effects | 1 |
74 | fracture-treatment | 1 |
75 | hygieia | 1 |
76 | hysterescopy | 1 |
77 | hβ1- | 1 |
78 | influence-self-efficacy | 1 |
79 | influences-efficacy | 1 |
80 | lectrajet | 1 |
81 | lipoprotein-precipitation | 1 |
82 | lwethu | 1 |
83 | m2.ncui | 1 |
84 | methylmalonyl-snac | 1 |
85 | micro® | 1 |
86 | mld50 | 1 |
87 | nexstent | 1 |
88 | non-5-ht | 1 |
89 | non-angulated | 1 |
90 | one-percentage | 1 |
91 | p.o.administration | 1 |
92 | pamir | 1 |
93 | phorophyte | 1 |
94 | phosphate-poly | 1 |
95 | post-dmards | 1 |
96 | pparg-retinoid | 1 |
97 | pre-ligands | 1 |
98 | probe- | 1 |
99 | r2n-c≡c-nr2 | 1 |
100 | response/guided | 1 |
101 | ribo- | 1 |
102 | rt/tmz | 1 |
103 | salan | 1 |
104 | snowshoe | 1 |
105 | srotomula | 1 |
106 | s∕n | 1 |
107 | takeback | 1 |
108 | taxpayer-funded | 1 |
109 | three-point-five-fold | 1 |
110 | thuringiensin | 1 |
111 | time-relative | 1 |
112 | time-to-angiography | 1 |
113 | time/ | 1 |
114 | time/dose | 1 |
115 | time=153±148 | 1 |
116 | times-to-exhaustion | 1 |
117 | times/inr | 1 |
118 | ulcertec® | 1 |
119 | £900 | 1 |
120 | α-1ar | 1 |
121 | β4*-nachrs | 1 |
1 | 'discovery | 1 |
2 | +1.0°c | 1 |
3 | -26.52 | 2 |
4 | -pmr | 1 |
5 | 0.01° | 3 |
6 | 1,2-dibromoethane | 1 |
7 | 1,2-manner | 1 |
8 | 1.6-17.0 | 1 |
9 | 10.7±2.2 | 1 |
10 | 15-30s | 1 |
11 | 16-years-old | 1 |
12 | 20-30-minute | 1 |
13 | 200d | 1 |
14 | 21,641 | 1 |
15 | 30-mins | 1 |
16 | 382-fold | 1 |
17 | 40months | 2 |
18 | 42-atom-antidot | 1 |
19 | 42-km | 1 |
20 | 44oc | 1 |
21 | 5,000mg/kg/day | 1 |
22 | 5.00-6000ng/ml | 1 |
23 | 500kwhm | 1 |
24 | 501/mm3 | 1 |
25 | 55-years | 2 |
26 | 5yr | 3 |
27 | 6000mgl | 1 |
28 | 70-year-olds | 2 |
29 | 95+/-11 | 1 |
30 | al-buqratiya | 2 |
31 | apy+at | 1 |
32 | apy+sal | 2 |
33 | atg1δ | 1 |
34 | ballasts | 1 |
35 | ballistocardiograms | 2 |
36 | bewertungsmabetastab | 1 |
37 | break-in | 1 |
38 | c2-carbon | 1 |
39 | case/images | 1 |
40 | cat-mv3glc- | 1 |
41 | cis-form | 1 |
42 | codon59 | 2 |
43 | cohorte | 1 |
44 | complications/time | 1 |
45 | complictions | 2 |
46 | cuprophan | 1 |
47 | d-phe-cys-tyr-d-trp-orn-thr-pen | 1 |
48 | days-to-months | 1 |
49 | dgu® | 2 |
50 | direct-detection | 1 |
51 | door-in | 1 |
52 | dose/time | 2 |
53 | efficacy-stopping | 1 |
54 | endpoints/time | 1 |
55 | envi-carb/nh | 1 |
56 | epikeratome | 1 |
57 | evlt™ | 1 |
58 | exacerbations-free | 1 |
59 | exposion | 1 |
60 | filtre | 1 |
61 | force-effects | 1 |
62 | fracture-treatment | 1 |
63 | hygieia | 1 |
64 | hysterescopy | 1 |
65 | hβ1- | 1 |
66 | influence-self-efficacy | 1 |
67 | influences-efficacy | 1 |
68 | ldhb | 2 |
69 | lectrajet | 1 |
70 | lipoprotein-precipitation | 1 |
71 | lwethu | 1 |
72 | m2.ncui | 1 |
73 | mans | 2 |
74 | methylmalonyl-snac | 1 |
75 | microfeatures | 2 |
76 | micro® | 1 |
77 | mini-monovision | 4 |
78 | mld50 | 1 |
79 | multcomp | 2 |
80 | nexstent | 1 |
81 | non-5-ht | 1 |
82 | non-angulated | 1 |
83 | non-driving | 3 |
84 | one-percentage | 1 |
85 | p.o.administration | 1 |
86 | pamir | 1 |
87 | pd4-9 | 2 |
88 | philopatry | 3 |
89 | phorophyte | 1 |
90 | phosphate-poly | 1 |
91 | post-dmards | 1 |
92 | pparg-retinoid | 1 |
93 | pre-ligands | 1 |
94 | pre-patent | 2 |
95 | probe- | 1 |
96 | r2n-c≡c-nr2 | 1 |
97 | response/guided | 1 |
98 | ribo- | 1 |
99 | rt/tmz | 1 |
100 | salan | 1 |
101 | snowshoe | 1 |
102 | srotomula | 1 |
103 | s∕n | 1 |
104 | takeback | 1 |
105 | taxpayer-funded | 1 |
106 | tens-of-micrometers | 2 |
107 | three-point-five-fold | 1 |
108 | thuringiensin | 1 |
109 | time | 94,828 |
110 | time-relative | 1 |
111 | time-to-angiography | 1 |
112 | time/ | 1 |
113 | time/dose | 1 |
114 | time=153±148 | 1 |
115 | times-to-exhaustion | 1 |
116 | times/inr | 1 |
117 | trochar | 2 |
118 | ulcertec® | 1 |
119 | £900 | 1 |
120 | α-1ar | 1 |
121 | β4*-nachrs | 1 |
1 | hβ1- | 1 |
2 | cat-mv3glc- | 1 |
3 | probe- | 1 |
4 | ribo- | 1 |
5 | time/ | 1 |
6 | 1.6-17.0 | 1 |
7 | £900 | 1 |
8 | mld50 | 1 |
9 | 95+/-11 | 1 |
10 | 21,641 | 1 |
11 | 10.7±2.2 | 1 |
12 | -26.52 | 2 |
13 | r2n-c≡c-nr2 | 1 |
14 | 501/mm3 | 1 |
15 | time=153±148 | 1 |
16 | pd4-9 | 2 |
17 | codon59 | 2 |
18 | hygieia | 1 |
19 | srotomula | 1 |
20 | al-buqratiya | 2 |
21 | bewertungsmabetastab | 1 |
22 | ldhb | 2 |
23 | methylmalonyl-snac | 1 |
24 | 44oc | 1 |
25 | +1.0°c | 1 |
26 | 200d | 1 |
27 | response/guided | 1 |
28 | taxpayer-funded | 1 |
29 | non-angulated | 1 |
30 | pparg-retinoid | 1 |
31 | 16-years-old | 1 |
32 | 382-fold | 1 |
33 | three-point-five-fold | 1 |
34 | exacerbations-free | 1 |
35 | one-percentage | 1 |
36 | time | 94,828 |
37 | dose/time | 2 |
38 | complications/time | 1 |
39 | endpoints/time | 1 |
40 | epikeratome | 1 |
41 | 1,2-dibromoethane | 1 |
42 | snowshoe | 1 |
43 | filtre | 1 |
44 | time/dose | 1 |
45 | cohorte | 1 |
46 | 20-30-minute | 1 |
47 | phorophyte | 1 |
48 | time-relative | 1 |
49 | efficacy-stopping | 1 |
50 | non-driving | 3 |
51 | envi-carb/nh | 1 |
52 | m2.ncui | 1 |
53 | takeback | 1 |
54 | apy+sal | 2 |
55 | 6000mgl | 1 |
56 | 5.00-6000ng/ml | 1 |
57 | 500kwhm | 1 |
58 | 42-km | 1 |
59 | cis-form | 1 |
60 | cuprophan | 1 |
61 | salan | 1 |
62 | d-phe-cys-tyr-d-trp-orn-thr-pen | 1 |
63 | break-in | 1 |
64 | door-in | 1 |
65 | thuringiensin | 1 |
66 | c2-carbon | 1 |
67 | mini-monovision | 4 |
68 | exposion | 1 |
69 | p.o.administration | 1 |
70 | lipoprotein-precipitation | 1 |
71 | direct-detection | 1 |
72 | times-to-exhaustion | 1 |
73 | s∕n | 1 |
74 | multcomp | 2 |
75 | α-1ar | 1 |
76 | trochar | 2 |
77 | 1,2-manner | 1 |
78 | pamir | 1 |
79 | -pmr | 1 |
80 | times/inr | 1 |
81 | 5yr | 3 |
82 | 15-30s | 1 |
83 | 70-year-olds | 2 |
84 | pre-ligands | 1 |
85 | post-dmards | 1 |
86 | case/images | 1 |
87 | microfeatures | 2 |
88 | days-to-months | 1 |
89 | 40months | 2 |
90 | ballistocardiograms | 2 |
91 | mans | 2 |
92 | 30-mins | 1 |
93 | complictions | 2 |
94 | 55-years | 2 |
95 | tens-of-micrometers | 2 |
96 | β4*-nachrs | 1 |
97 | force-effects | 1 |
98 | ballasts | 1 |
99 | apy+at | 1 |
100 | lectrajet | 1 |
101 | non-5-ht | 1 |
102 | fracture-treatment | 1 |
103 | pre-patent | 2 |
104 | nexstent | 1 |
105 | 42-atom-antidot | 1 |
106 | lwethu | 1 |
107 | 5,000mg/kg/day | 1 |
108 | influence-self-efficacy | 1 |
109 | influences-efficacy | 1 |
110 | time-to-angiography | 1 |
111 | phosphate-poly | 1 |
112 | hysterescopy | 1 |
113 | 'discovery | 1 |
114 | philopatry | 3 |
115 | rt/tmz | 1 |
116 | evlt™ | 1 |
117 | ulcertec® | 1 |
118 | micro® | 1 |
119 | dgu® | 2 |
120 | 0.01° | 3 |
121 | atg1δ | 1 |